Table 1.
Manifestations related to CanL defined to evaluate the clinical scores of dogs.
Fig 1.
Consort flow diagram showing the therapeutic protocols and dogs with leishmaniasis in each stage of the study.
Over all the 42 dogs included at D+0, one dog from the Group 2 was lost to follow-up before the D+30 time point. During the 6-month follow-up, four dogs from Group 1 were lost to follow-up two months after the beginning of treatment, and two of these were due to failure of clients to return for the final revisits on D+90 and D+180. Two others were because of death not related to CanL. In addition, six dogs died in the period between D+60 after the beginning of treatment and before the D+90 visit with increase in clinical signs related to CanL. Four of these were in Group 1, and two were in Group 2.
Table 2.
Characteristics of dogs assigned to each treatment arm and homogeneity analysis data, expressed as the mean ± standard deviation and frequencies (%).
Fig 2.
Time course of total clinical score (Kruskal-Wallis test).
Clinical scores (mean ± SD) of the dogs (n = 42) were assessed by veterinarians at the time of scheduled visits at D0, D+30, D+90 and D+180. A. All treated groups. B. Glucantime/Allopurinol-treated group. C. Artesunate-treated group.
Fig 3.
Comparison of the mean percent reduction in clinical score between groups (Mann-Whitney test); A. Day 30 posttreatment; B. Day 90 posttreatment; C. Day 180 posttreatment. Mortality was taken into consideration (mortality score = 22). The mean percent reduction in clinical score is higher in the artesunate-treated group than in the Glucantime/allopurinol-treated group at all time points.
Table 3.
Individual clinical changes in dogs over time.
Table 4.
Individual change in parasite load, number of parasites per mL of blood and percentage reduction over time.
Fig 4.
Antibody titers (mean ± SD) of the dogs (n = 42) were assessed by quantitative IFAT at the time of scheduled visits at D0, D+30, D+90 and D+180 (Kruskal-Wallis test/bilateral). A. All dogs. B. Glucantime/allopurinol group. C. Artesunate group.